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Targeting of Cytotoxic T Cells  Against  Leukemic B Cells by 
Bispecific Antibody (aCD3 X aCDl9) Does not Distract the T 
Cell From I t s  Primary Target' 
S, C. Klein,* S .  H. van der Burg,* 1. H. Boer,* C. J. M. Melief,* W. M. Kasf,§ C. C. de Gast,* 
and E. J. E. G .  Bast*2 
Bispecific  Abs  (BsAb) represent  a novel format of immunotherapy,  recognizing immune effector  cells  (e.g., T cells), on the  one 
hand,  and  target  cells  (e.g., tumor cells),  on the other  hand. To be successful,  cross-linking of the two cell types i s  necessary  for 
effector cell activation and subsequent killing of the malignant target cells. We asked the question, whether CTL that were 
incubated with the BsAb aCD3 X aCD19 and malignant B cells and activated to kill the malignant B cells were still able to 
eliminate their natural target cells  (e.g., virus-infected  autologous  body  cells). To test  this, HLA-A*0201 -restricted, influenza- 
specific CTL were incubated with BsAb- and HLA-A*0201-positive B lymphoid  tumor cells in combination with HLA-A*0201- 
positive,  virus-infected,  non-B lymphoid cells as natural target cells.  The  results  showed that  even in the presence of BsAb  and 
high  amounts of tumor B cells, CTL were still  capable of eliminating the  virus-infected  non-B lymphoid target cells; actually, CTL 
recognized  and eliminated the homologous original target cells preferentially. The journal of Immunology, 1997, 159: 5545- 
5549. 
ispecific Abs ( B s A ~ ) ~  consist of two different heavy and 
light chains  and may bind to two different Ag present on 
different cell  types. With their dual specificity, BsAb may 
recognize immune effector cells (e.g., T cells), on the one hand, 
and tumor target (e.g., malignant B) cells. on the other hand. To be 
successful, cross-linking of the  two cell types is necessary (in com- 
bination with a second signal) for optimal effector (e.g., T cell) 
activation and subsequent cytotoxicity against the malignant (B) 
cells (1-3). The model BsAb aCD3 X aCDl9 that we used can 
retarget autologous T cells to malignant B cells (4) and has been 
tested in non-Hodgkin's lymphoma (NHL). NHL is a frequently 
occurring malignancy of the lymphoid system in which the ma- 
lignant  cells in most cases belong to the B cell lineage and express 
the CD 19 Ag. 
In vitro studies have shown that B cells can be lysed by cyto- 
toxic T cells in the presence of BsAb (4-7). The BsAb-mediated 
lysis was highly specific and independent of HLA class I expres- 
sion (4, 8). A phase I trial using the BsAb CD3xCD19 showed 
little toxicity and some T cell activation (9). In vitro experiments 
suggested that the clinical responses to BsAb therapy could be 
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enhanced by additional T cell activation, e.g., using a second sig- 
nal such as IL-2 (10). In the following phase 1/11 trial, patients were 
treated with BsAb in combination with S.C. low dose IL-2 ( 1  1). 
The study described here was initiated because of the first pa- 
tient in that phase UII trial. This patient (a 63-yr-old man) was 
diagnosed with chronic lymphocytic leukemia in 1989. He was 
refractory for Leukeran (Wellcome, England) and was treated with 
cyclophosphamide/vincristine/procarbazin, From December 1990 
to March 1992, he was treated with fludarabine, which gave a 
partial response. After 1 yr, he relapsed and was treated again with 
fludarabine. In 1994, the chronic lymphocytic leukemia pro- 
gressed, and the patient was treated six times with cyclophospha- 
mide/adriamycin/vincristine/procarbazin without obvious results. 
In November 1994, this patient entered the phase MI study, and  he 
was treated with BsAb aCD3 X aCD19 in combination with S.C. 
JL-2. Some weeks later, the patient developed a severe herpes 
zoster (shingles pox) infection, which was treated with Aciclovir 
(Zovirax, Wellcome, England). We wondered whether this virus 
infection could be due to the treatment with BsAb or, as a more 
general question, whether T  cells exposed to BsAb to kill malig- 
nant B cells would still be capable to eliminate their original target 
cells. 
To address this question, we compared the effects of BsAb on 
the cytotoxicity of influenza-specific CTL for a virus-infected 
non-B cell line, SW620, as well as against the B lymphoid cell line 
JY (lymphoblastoid B cell) and vice versa. The results show that 
the process of virus-specific T cell cytotoxic killing prevails over 
BsAb-dependent B  cell killing. 
Materials and Methods 
Cell lines 
JY (CD19') is an EBV-transformed  lymphoblastoid  cell  line and is pos- 
itive  for MHC class I HLA-A*0201 (12). JY was grown in RPMI 1640 
Dutch Modificarion  (Life Technologies, Paisley, Scotland) supplemented 
with 10% FCS and 20 pM 2-ME (Merck,  Darmstadt, Germany). 
SW620 is a colon  adenocarcinoma  (American  Type  Culture  Collection 
CCL227,  Rockville, MD) adherent cell  line also expressing the MHC class 
0022-1  767/97/$02.00 
5546 Ag-SPECIFIC vs BsAb-MEDIATED T CELL INTERACTION 
I molecule HLA-A*0201. Cells were grown in Leibovitz L-15 medium 
(Life Technologies) supplemented with 10% FCS (L-15-10; Life Tech- 
nologies) and passaged weekly. 
The  SW620/CD19 cell line was developed by transfecting SW620  cells 
with vector pHZM-B7-19 carrying the cDNA encoding the human CD19 
Ag (2).  Cells were transfected by electroporation and selected in  250 and 
500  pg/ml hygromycin (Calbiochem, La Jolla, CA).  CD19 expression was 
tested by FACS analysis. 
The influenza matrix-specific, HLA-A*020Lrestricted  CTL  clone 
466.9 (a  gift from Dr. H. Spits,  Netherlands Cancer Institute, Amsterdam, 
The Netherlands) recognizes the influenza virus MHW68-encoded  epitope 
GILGFVFTL. The CTL clone was grown on irradiated (30 Gy) HLA- 
A*OZOI-positive EBV-transformed B cells in RPMI 1640 supplemented 
with 10% human serum, 120 IU of rIL-Z/ml (Eurocetus, Amsterdam, The 
Netherlands), and 1.5 pg/ml leukoagglutinin (Sigma Chemical Co., St. 
Louis, MO).  Cells were tested for their cytotoxic activity, frozen in batches 
of 2 X lo6 cells/vial, and kept in liquid nitrogen until use. 
Infection with influenza virus 
SW620 cells were cultured for  48  h in the presence of 200 IU of human 
IFN-y/ml (PeproTECH, Rocky Hill, NJ) before infection. Three to five 
million cells were infected with 100 infectious units of influenza virus 
NHW68 (Hong Kong 1968; a  gift from Prof. Dr. Mazurel, Erasrnus Uni- 
versity, Rotterdam, The Netherlands). Cells were washed with L-15 con- 
taining 1% FCS, then incubated with virus for 1 h at 37OC. Cells were 
washed with L-15-10 and then cultured in L-15-10 for  16  h at 37°C. 
BsAb CD3xCD 19: SUR 1 
The  aCD3 X aCD19 BsAb-secreting clone  SHRl  is  a fusion product be- 
tween the cell lines YTH12.5 and MGlCD19. YTH12.5 is a rat IgG2b 
mAb with a specificity for  the human CD3e Ag (13). MGlCD19  is  a mouse 
IgGl  mAb and recognizes the human CD19 Ag. The production and pu- 
rification of the BsAb SHRl (aCD3 X aCD19) have been previously de- 
scribed (14). The BsAb SHRl was used as complete Ab, including the 
Fc part. 
"Cr release  assay 
Cytotoxicity was measured in a standard 51Cr release assay. All determi- 
nations were performed in triplicate. Briefly, 2 X IO6 target cells were 
incubated with 100 pCi (3.7 MBq) of  Na, 5'Cr04 (Amershani, Aylesbury, 
U.K.) for 1 h  at 3 7 T .  After labeling, target cells were washed twice with 
medium and adjusted to 4 X IO4 celUml, and 50 p1 was added to 50 *I of 
various amounts  of effector cells, 50 pl of BsAb/medium, and 50 pI of 
nonlabeled target cells, al l  seeded in wells of U-bottom microtiter plates 
(Costar, Badhoevedorp, The Netherlands) in a final volume of 200 pI. 
After 4  h of incubation the supernatant was harvested using the Skatron 
harvesting system (Skatron, Oslo, Norway), and chromium release was 
measured in a  gamma  counter (Minimax, Auto gamma counter, Packard 
Instrument Co, Meriden, CT). Maximum release was determined by incu- 
bating the target cells in 1% Triton X-100; spontaneous release was mea- 
sured by incubating the target cells with medium alone. The percent spe- 
cific 51Cr release was calculated using the formula: % specific release = 
[(experimental release - spontaneous release)/(maximal release - spon- 
taneous release)] X 100. 
Cold target inhibition 
Possible inhibition of lysis of infected SW620 target cells was tested by 
preincubating 466.9 effector cells with different amounts  of unlabeled JY 
cells in the presence of BsAb. After I h of preincubation of JY  and Q66.9 
cells in the presence of BsAb at 37"C, the chromium-labeled SW620 target 
cells were added. Supernatant was harvested after 4  h of incubation. 
Inhibition of BsAb-mediated lysis of JY cells was tested by simulta- 
neously adding different amounts of unlabeled infected SW 620 target 
cells. 
Immunofluorescence studies 
mAbs against CD3,  CD19, CD20, CD45/CD14, HLA class I, and HLA-DR 
were purchased from Becton Dickinson (Becton Dickinson, Mountain 
View, CA). Abs binding to B7-1 (B7-24) and B7-2 (IG10, both unlabeled) 
were gifts from Dr. Mark de Boer (Innogenetics Ghent, Belgium). Abs 
binding to LFA-1 and ICAM-1 were gifts from Dr. Andries Bloem (Utre- 
cht,  The Netherlands). Unlabeled Abs were used in indirect stainings fol- 
lowed by goat anti-mouse Ig coupled  to FITC. All mAb incubations and 
washing steps were performed at 4°C in PBS supplemented with 1% BSA 
and 0.01% NaN,. Fluorescence was quantified using a FACScan (Becton 
Dickinson). 
Results 
Killing of homologous  target cells (SW620) 
The  colon carcinoma cell  line SW620 was either noninfected or 
infected with the influenza virus A/HW68  and used as the target 
cell. The labeled cells were incubated with the cytotoxic T cell line 
466.9 in the absence or the presence of the B cell line JY and in 
the  absence or the presence of the BsAb (Fig. 1A and  Table I). 
Cytotoxic T cells (466.9) did not kill noninfected SW620 target 
cells (negative control). Virus APHW68-infected target cells were 
properly killed (positive control), which was not affected by the 
presence  of the BsAb. If B cells (JY) were added to the CTL plus 
virus-infected SW620  (SW620N) target cells, the killing of the 
homologous target cells was not affected. The killing of virus- 
infected SW620 target cells by cytotoxic T cells in the presence of 
both B cells plus the BsAb was again not affected even with a 10- 
or 50-fold excess of the B cells. Collectively, the virus-infected 
target cells were killed in the same percentage range as those with- 
out the B cells and/or the BsAb. 
BsAb-mediated killing  of B cells (JY) 
The B cell line JY was labeled with 5'Cr and incubated with the 
cytotoxic T cell clone 466.9 in the presence or the absence of 
BsAb  and  in  the presence or the absence of the homologous virus- 
infected non-B target cells (Fig. 1B and Table 11). 
Cytotoxic T cells (466.9) incubated with the B cell line J Y  but 
without the BsAb did not kill the B cells (negative control), as 
expected. In the presence of the BsAb the B cells were killed 
(positive control); this was not inhibited by the presence of non- 
infected SW620 target cells. T cell-dependent BsAb-mediated B 
cell kill was influenced, however, by the presence of virus-infected 
SW620 target cells; B cells were still killed but the presence of a 
minor proportion of virus-infected SW620 cells (O.l*SW620 = 
10% of the total target cells) inhibited BsAb-mediated killing of 
the B cells. When virus-infected SW620 cells were added at a ratio 
of 1:l (infected SW620 cells to B cells) or lO:l, the killing of the 
B cells was even more inhibited. 
In conclusion, in the presence of BsAb and high amounts of 
tumor B cells, T cells still recognized the homologous target cell 
specificity and were able to eliminate these target cells preferen- 
tially. Actually, T cells preferentially killed the virus-infected 
non-B target cells. Even in the presence of high amounts of tumor 
B cells and BsAb, the original target cell-reactive killing of the 
specific T cells is maintained. 
Killing of S W62O/CD 19 cells 
We tested whether differences in cytotoxicity toward virus-in- 
fected SW620 cells and the J Y  B cell line, respectively, as de- 
scribed above, were dependent on differences in the intrinsic sus- 
ceptibility of the respective target cells. SW620 is an adherent 
growing carcinoma cell line, whereas J Y  is a nonadherent growing 
leukemic line. To approach this question, we transfected cell line 
SW620 with vector pHZM-B7-19, which carried cDNA encoding 
the human CD19 Ag and selected transfected cells with hygromy- 
cin.  Together  Figure 1 and 2 show that the cytotoxic T cells 466.9 
killed neither the original SW620  cells (negative control) (Fig I )  
nor the CDl9-expressing SW620 cells (SW620/CD19) (Fig. 2). 
These  SW620/CD19  cells, however, were killed in the presence of 
BsAb (SW620KD19 plus BsAb), but not to the  same extent as the 
virus-infected SW620  cells (SW620N, positive control). 
Discussion 
Since a patient treated with BsAb and S.C. IL-2 developed a serious 
herpesvirus infection after the treatment, we wondered whether T 
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FIGURE 1. Cytotoxicity  of T effector cells against natural target cells  and B cells. The cytotoxicity  of  the effector cells 466.9 against the target 
cells SW620 (colon  carcinoma; A )  or JY (B cell; B)  is assayed in a "Cr release assay. Target cells SW620 or JY were  incubated  with  the effector 
cells 466.9 under  the  conditions  indicated  with  or  without  the BsAb and  with  or  without the other  (cold) target cells as possible competitors. The 
percentage of  "Cr release is displayed at various E:T cell ratios. The colon  carcinoma  cells  were  either  noninfected  (control) o r  infected with the 
influenza  virus (V). Cold target cells  were used in a 0.1 -, 1 -, lo-, or 50-fold excess. 
Table I. Killing of infected target cells (SW620/AHKl by T eifector 
cells 
Lysis 
"Cr  Labeled SW620 Target Cells Expected Observed 
Cytotoxic  T  cells + noninfected target cells - 
Cytotoxic  T  cells + infected target cells + " + 
Cytotoxic T cells + infected target cells + + + 
Cytotoxic  T  cells + infected target cells + BsAb + + 
Cytotoxic  T  cells + infected target cells + ? + 
Cytotoxic T cells + infected target calls -t ? + 
- 
B cells (JY) 10x/50x' 
B cells iJY)lOx + BsAb 
B cells (JY)SOx + BsAb 
'' -, no killing. ' +, killing. 
' 10X/50X more B cells (JY) than  infected target cells (SW620). 
Table (I. Killing of D cells (JY) by T effector cells 
Lysis,' 
"Cr Labeled JY E Cells Expected Observed 
Cytotoxic T cells + B cells (JY) - 
Cytotoxic T cells + B cells (JY) + BsAB + + 
Cytotoxic T cells + B cells (JY) + + + 
noninfected target cells + BsAb 
Cytotoxic T cells + B cells (JY) + 
infected target cells ( lox) + BsAb 
? (-1 
Cytotoxic T cells + B cells (JY) + ? ( + I  
infected target cells (1 x) + BsAb 
Cytotoxic  T  cells + B cells (JY) + ? + 
infected target cells (0 .1~ )  + BsAb 
- 
undetermined. 
-, no killing; +, killing; (+), reduced  killing; ( - 1 ,  highly  reduced  killing; ?, 
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FIGURE 2. Cytotoxicity of T effector cells against CD19-transfected SW620 cells (SW620/CD19). The cytotoxicity of the effector cells 466.9 
against the CD19-transfected SW620 (colon carcinoma) (SW620/CD19) is analyzed in a 5’Cr  release  assay.  Target cells SW620  or SW620KD19 
were incubated with the effector cells 466.9 under the conditions indicated with or without the BsAb. The percentage of 5’Cr  release is displayed 
at  various E:T cell  ratios.  The colon carcinoma celk were either  noninfected (control) or  infected with the influenza virus (V). 
cells that are targeted with BsAb toward malignant B cells  were 
still able to defend the body against infectious agents and whether 
the treatment with BsAb would induce a T cell immunodeficiency. 
The  experiments performed here to address this question showed 
that T cells were still capable of recognizing their natural target 
cells and kill them; in fact, the natural target cells were killed 
preferentially, even with preincubation of T cells and B cells in the 
presence of the BsAb and later addition of non-B natural target 
cells. 
Why  do the T cells prefer the natural virus-infected target cells 
SW620 in the presence of B cells JY and BsAb?  Three  points merit 
attention, i.e., the mechanisms governing the interaction between 
effector and target cells, the mechanism of cytotoxicity in  the ef- 
fector  cell,  and the comparative susceptibilities of the two  target 
cells. 
In the first point (the avidity of the interaction between effector 
and target cells), three aspects merit discussion, i.e., the affinity of 
the specific binding, the presence of accessory molecules, and the 
comparative antigen densities. The TCR complex recognizes a 
peptide lodged in the peptide binding groove of MHC  class I or IT 
molecules with an affinity of about M (IS, 16). The afKnity 
of this specific interaction is lower than that in  the BsAb system, 
as both CD3 and CD19 parental Ab expressed affinities in the 
range of to IO-” M. The affinities of the CD3 and CD19 parts 
of the BsAb were similar to those of the parental mAbs (17), in- 
dicating that the affinity of the specific BsAb-mediated T-B inter- 
action supersedes that of the T-SW620 interaction. 
To enhance the affinity of cellular interactions, additional li- 
gands are involved in binding and signaling. These accessory mol- 
ecules in the interaction between cytotoxic T cells and their target 
cells may include LFA-1, CD2, and CD28. ICA”1 is known to 
interact with LFA-1, which is present on all immune cells. The 
CD2 molecule on T cells is also involved in T cell activation in 
conjunction with TCR; it is a receptor for LFA-3, which is ex- 
pressed on many different cell types and present on  all APCs. The 
most important costimulatory molecules known are termed B7-1 
(CD80) and B7-2 (CD86), which are ligands for CD28 as well as 
its homologue  CTLA-4, a molecule that is expressed on T cells and 
up-regulated during T cell activation. In these experiments, the 
HLA  class I Ag expression on the B cells and that on the colon 
carcinoma cell line SW620 are identical, and HLA class I differ- 
ences should not play any role.  Moreover, it has been shown that 
BsAb-mediated killing is independent of HLA class I d1Eerences 
or expression of ICAM-1, B7, and LFA-1 molecules (4, IO). The 
target cells were tested far the expression  of second signal mole- 
cules; JY cells  are positive for B7- 1, B7-2, and ICAM- 1, whereas 
the virus-infected target cell line SW620 does not express these 
accessory molecules (Table 111). 
Ag densities governing specific interaction may pertain to CD3 
(identical in both systems) and CD19 vs viral peptide-expressing 
MHC class I molecules. By using viral infection in culture (as used 
here), Falk et al. found that the proportion of viral peptide-loaded 
MHC molecules approximates 0.1 to 0.5% of the total expression 
of MHC  class I molecules (18, 19); the latter i s  in the same range 
as the expression of CD19  on  the B cells. All three aspects men- 
tioned for the avidity of the interaction (i.e., affinity, accessory 
molecules, and Ag density)  seem to favor the BsAb-mediated T-B 
cell interaction, which is apparently not the case. 
The two other factors include mechanism of cytotoxicity (in 
both systems dependent of the granzyme/perforin pathway (S. C. 
Klein, unpublished observations) or susceptibility of the target 
cells. Reportedly, necessary E:T cell ratios in T cell-dependent, 
BsAb-mediated tumor killing are higher in carcinoma cell lines 
than in B cells (8), possibly indicating a lower intrinsic suscepti- 
bility of adherent growing carcinoma cells for T cell lytic pro- 
cesses. Our results might indicate just the reverse situation, i.e., 
higher sensitivity of the virus-infected carcinoma cells. To test 
whether the  two different mechanisms of recognition taking place 
on the cell surface of the  same  cell might result in different IeveIs 
of induced cytotoxicity, we transfected SW620 cells with CD19 
cDNA and tested the susceptibility of these cells in a BsAb-me- 
diated system  compared with that in virus-infected SW620 cells. 
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Table 111. Expression of cell surface markers as determined by 
immunofluorescence 
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As the density of CD19 on the SW620/CD19  cell line is  compa- 
rable with that of JY, and  as intrinsic differences in both target cell 
susceptibility and effector cell efficacy can be ruled out in this 
system, these findings reinforce the idea that virus-dependent kill- 
ing prevails over BsAb-mediated killing. Given the preference for 
virus-specific killing over BsAb-mediated killing, as shown here, 
what, then, is the prospect of BsAb-mediated treatment of malig- 
nancies? As  the frequency of T cells specific for  a given Ag is low 
even in acute viral infections, a host of other T cells can be in- 
volved in BsAb-mediated B cell killing. 
Collectively, despite the “less favored’ conditions, low TCR 
affinity, no expression of accessory molecules, and low Ag density, 
the virus-infected target cells are preferred over BsAb-mediated 
killing; differences between processes of cytotoxicity or sensitivity 
of cells cannot explain this preference. 
However, very recent data on T cell activation seem to indicate 
that a low avidity of the  MHC  class IYTCR interaction suffices, or 
may even be preferred, for T cell activation (20). To our knowl- 
edge, it is not known whether this preference also applies to the 
MHC class vTCR interaction of cytotoxic T cells; our data on the 
comparison of three different anti-CD3LD19 BsAb in the medi- 
ation of T cell cytotoxicity from preactivated T cells  seem to in- 
dicate  a positive influence of the affinity of CD3 recognition. 
Apart from these basic immunologic aspects, the presented data 
deserve clinical interest as well. In iatrogenic T cell immunodefi- 
ciencies, e.g., after transplantation and consecutive immunosup- 
pression, endogenous viruses, especially herpesviruses such as 
HSV, VZV, CMV, and EBV, can recur and give rise to problems 
(21). Also, de novo infections may not be dealt with properly (22). 
In the patient who motivated these studies, the recurrent HSV in- 
fection is unlikely to be due to the experimental BsAb treatment 
for his NHL, however. Alternatively, his pretreatment situation 
involving fludarabine probably underlies this recurrent infection. 
Finally, these findings pertain to tumor immunology as well. In 
the murine system, possibly through enforced Ag presentation, 
BsAb treatment seems to result in  a tumor-specific immunity. Mice 
bearing transplantable EBV-infected tumorigenic B cells could be 
treated successfully with BsAb on day 3 after transplantation. 
When these treated mice  were rechallenged with the  same tumor, 
they were resistant in tumor growth, apparently specifically, as 
another transplantable tumor was not rejected (23). Our findings 
indicate that this tumor-specific immunity will not be hampered by 
further addition of BsAb. 
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